ICCC Q4 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+45.4% YoY

Gross Profit

$3M47.0% margin

Operating Income

$145,4122.7% margin

Net Income

$74,1341.4% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+5.7%

Cash Flow

Operating Cash Flow

$587,893

Free Cash Flow

-$116,701

Stock-Based Comp.

$40,931

Balance Sheet

Total Assets

$44M

Total Liabilities

$12M

Stockholders' Equity

$33M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+45.4%
Gross Profit	$3M	$2M	+58.0%
Operating Income	$145,412	-$634,000	+122.9%
Net Income	$74,134	$189,000	-60.8%

Revenue Segments

FirstDefenseProductLineMember

$5M99%

OtherAnimalHealthMember

$40,5951%

Geographic Segments

UNITED STATES

$4M82%

OtherStatesMember

$984,57418%